Navigation Links
Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
Date:7/15/2008

Most Up-to-Date Analysis of the Alzheimer's Disease Market Now Available

from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with Myriad Genetics/Lundbeck's decision to discontinue the development of Flurizan, the most likely first-to-market disease-modifying Alzheimer's disease treatment becomes Elan/Wyeth's bapineuzumab, an anti-beta-amyloid monoclonal antibody, expected to launch in 2011. The recent Phase III failure of Flurizan underscores the risk involved with developing an agent for Alzheimer's disease.

Decision Resources also finds that both bapineuzumab and Eli Lilly's LY-2062430 will quickly become blockbusters shortly after their launch due to their efficacy and high price point. The widespread use of these agents will depend, in part, on their safety and the complementary use of new diagnosis techniques that would permit patients to be diagnosed in the early stages of the disease, when disease-modifying therapies provide the greatest therapeutic benefit.

"We await Phase III results of the bapineuzumab trials with great interest, both in terms of the drug's safety profile, but also its efficacy in Alzheimer's disease patients carrying the ApoEe4 gene (which is a risk factor in Alzheimer's disease) compared with non-ApoEe4 gene carriers," states Andrea Witt, Ph.D., director at Decision Resources. "Should efficacy prove poor in ApoEe4 gene carriers, patients will be faced with the difficult decision of whether they would want to know whether they carry this gene. Nevertheless, even if bapineuzumab benefits only the non-ApoEe4 gene carriers-a prospective population of 40 to 70 percent of Alzheimer's disease patients-bapineuzumab stands to reap considerable profits in the Alzheimer's disease market."

Two new Decision Resources Alzheimer's disease reports-the Pha
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
3. Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
6. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
7. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
8. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
11. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... VIEJO, Calif. , Sept. 3, 2015 /PRNewswire/ ... global pharmaceutical company, and AqueSys, Inc. a private ... ocular implants that reduce intraocular pressure (IOP) associated ... into an agreement under which Allergan will acquire ... of the agreement, Allergan will acquire AqueSys for ...
(Date:9/3/2015)... Research and Markets( http://www.researchandmarkets.com/research/fw4ctl/investigation ) has ... China,s Entecavir Market, 2010-2019" report to their offering. ... B virus (HBV) exceeds 100 million in ... chronic Hepatitis B. About 0.5 million Chinese is estimated ... by chronic Hepatitis B, causing a loss of over ...
(Date:9/3/2015)... -- Research and Markets ( ... "Global Craniomaxillofacial (CMF) Devices Market 2015-2019" ... craniomaxillofacial devices market to grow at a CAGR ... the present and future scenario of the global ... market size, we use revenues generated from the ...
Breaking Medicine Technology:Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6China Entecavir Market Report 2010-2019 2Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2
... , ... 2008 amounted to over $1 billion in the European Union ... inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. ... fresh recommendations and treatment guidelines that call for using dopamine ...
... 8 Supermarket retailer Giant Eagle® Inc., is receiving an ... at the 12th Annual Cheers Awards reception held in Las ... have set a superlative standard of excellence for others to ... events. , The Giant Eagle Pharmacy ...
Cached Medicine Technology:Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2
(Date:9/3/2015)... ... September 03, 2015 , ... The first part of a ... made by IVC filter lawsuits filed against Bard.** These lawsuits, filed by ... Bard IVC filter broke or failed, have recently been consolidated for pretrial proceedings as ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, binge ... joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu collaborates ...
(Date:9/3/2015)... CANADA (PRWEB) , ... September 03, 2015 , ... ... today announced that it will be spotlighting its award-winning print and artwork inspection solutions, ... Vision team September 16 and 17 at the Olympia London, booth #F33 , Be ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers is again ... champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 ... to enjoy Thanksgiving and Christmas with an extra big smile. , This adorable ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
Breaking Medicine News(10 mins):Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4
... Tampa, Fla. (July 1, 2009) The frontiers of ... current issue of Cell Transplantation (Vol. 18 ... . Two studies are highlighted, one by a Brazil-based ... cell delivery methods following myocardial infarction, and a second ...
... , , , New study reports on posterior ... ROSEMONT, Ill., July 1 While major advances have been made in ... and reconstruction, a literature review published in the July 2009 issue of ... Orthopaedic Surgeons ( JAAOS ) finds that there must ...
... , Dedicated to advancing scientific research in regenerative medicine ... of universities, life sciences companies, health care investors, and ... therapies united today to launch the Alliance for Regenerative ... Washington, DC, the Alliance is dedicated to promoting regulatory, ...
... ET) Tufts dental researchers conducted a three-year follow-up study ... gums and found that complete root coverage the goal ... regeneration application, developed at Tufts, reduces the considerable pain and ... six patients is published in the July 2009 issue of ...
... Hospital has uncovered the biological effects of a novel ... for hormonal therapy for breast cancer. The study is ... Endocrinology. This new study by Edward Filardo, ... work by the group that linked the transmembrane receptor, ...
... early arthritis , , ROSEMONT, Ill., July 1 ... The condition occurs when a hip joint is shallow, unstable or when ... of developing arthritis of the hip as a ... of The Journal of Bone and Joint Surgery (JBJS) ...
Cached Medicine News:Health News:Cell transplantation and cardiac repair 2Health News:Cell transplantation and cardiac repair 3Health News:The 'Other' Cruciate Ligament: Newer Treatments for PCL Tears 2Health News:The 'Other' Cruciate Ligament: Newer Treatments for PCL Tears 3Health News:Alliance for Regenerative Medicine Launches 2Health News:New treatment for receding gums: No pain, lots of gain 2Health News:New treatment for receding gums: No pain, lots of gain 3Health News:Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer 2Health News:Infants Should Be Screened for Hip Trouble 2Health News:Infants Should Be Screened for Hip Trouble 3
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Single Use Loading Units (SULU's) with Titanium Staples for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Providing maximum versatility and maneuverability, the Articulator 35 is the only stapler for use in endoscopic and open procures that provides greater access to targeted structures with limited oper...
Medicine Products: